{"id":871571,"date":"2025-08-06T10:30:54","date_gmt":"2025-08-06T14:30:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/"},"modified":"2025-08-06T10:30:54","modified_gmt":"2025-08-06T14:30:54","slug":"revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/","title":{"rendered":"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics"},"content":{"rendered":"

<\/p>\n

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics<\/b><\/p>\n

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research<\/b><\/p>\n

WALTHAM, Mass.–(BUSINESS WIRE<\/a>)–Revvity, Inc.<\/a> (NYSE: RVTY), today announced the launch of pHSense\u2122<\/a> reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization.<\/p>\n

\nDeveloped for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to-background<\/a>\u2014even at low endogenous receptor expression levels. Fully compatible with Revvity\u2019s multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows. By enabling more efficient screening and characterization of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation.<\/p>\n

\n\u201cpHSense reagents fill a critical gap in internalization assay technologies, directed towards enabling researchers to gain faster, more reliable insights using more physiologically relevant conditions,\u201d said Craig Monell, senior vice president, reagents at Revvity. \u201cWith this launch, Revvity reinforces its commitment to advancing drug discovery through innovative tools that are focused on improving data quality, throughput, and reproducibility.\u201d<\/p>\n

\nWith a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design focused on addressing major limitations of current offerings such as low throughput and suboptimal signal-to-noise ratios.<\/p>\n

\nFor details on Revvity\u2019s wide-ranging portfolio of reagents \u2013 including immunoassays, gene editing and modulation tools, primary and secondary antibodies, and molecular biology solutions \u2013 visit www.revvity.com\/reagents<\/a><\/p>\n

About Revvity<\/b><\/p>\n

\nAt Revvity, \u201cimpossible\u201d is inspiration, and \u201ccan\u2019t be done\u201d is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what\u2019s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.<\/p>\n

\nWith 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.<\/p>\n

\nStay updated by following our Newsroom<\/a>, LinkedIn<\/a>, X<\/a>, YouTube<\/a>, Facebook<\/a> and Instagram<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250806348537\/en\/<\/a><\/span><\/p>\n

Investor Relations:
\n<\/b>
Steve Willoughby
\n
steve.willoughby@revvity.com
\n<\/a><\/p>\n

Media Relations:
\n<\/b>
Chet Murray
\n
(781) 462-5126
\n
chet.murray@revvity.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Software Research Hardware Pharmaceutical Oncology Technology Medical Devices Health Technology Science Biotechnology Other Technology Health Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense\u2122 reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high … <\/p>\n

Continue reading “Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-871571","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense\u2122 reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high … Continue reading "Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-06T14:30:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics\",\"datePublished\":\"2025-08-06T14:30:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/\"},\"wordCount\":515,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/\",\"name\":\"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-08-06T14:30:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics - Market Newsdesk","og_description":"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense\u2122 reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high … Continue reading \"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-06T14:30:54+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics","datePublished":"2025-08-06T14:30:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/"},"wordCount":515,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/","name":"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-08-06T14:30:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250806348537r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-innovative-reagent-technology-to-accelerate-development-of-next-generation-targeted-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/871571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=871571"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/871571\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=871571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=871571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=871571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}